May. 17 at 8:36 PM
$XBIO
Not a lot of eyes are watching XBIO right now, but something’s shifting under the radar. Price pulled back slightly this week, closing at 2.91, which is a healthy breather considering the YTD return still sits over 27%. That correction was on lower volume, which usually doesn’t scream panic. The Q1 earnings just dropped with revenue ticking in at 446k, not massive, but paired with ongoing updates on their DNase oncology platform, it’s enough to keep long-term speculative holders engaged. The biotech micro-cap space is tricky, especially when market cap dips under 5M, but those who read between the lines caught the recent poster presentation at SITC and noticed the subtle traction that could evolve into something bigger. It’s not all charts and earnings — sometimes it's about timing and narrative. Always DYOR.
